Lisa Walter
Stock Analyst at RBC Capital
(4.14)
# 462
Out of 5,148 analysts
14
Total ratings
58.33%
Success rate
19.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Outperform | $45 → $42 | $30.25 | +38.84% | 3 | Feb 27, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $587 → $643 | $513.82 | +25.14% | 3 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $22 → $21 | $20.70 | +1.45% | 2 | Feb 25, 2026 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $145 | $94.94 | +52.73% | 1 | Feb 19, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $7.58 | +111.08% | 1 | Nov 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $26 → $32 | $9.33 | +242.98% | 2 | Nov 11, 2025 | |
| EYPT EyePoint | Maintains: Outperform | $28 → $39 | $18.34 | +112.65% | 2 | Nov 6, 2025 |
Viridian Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $45 → $42
Current: $30.25
Upside: +38.84%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $587 → $643
Current: $513.82
Upside: +25.14%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $21
Current: $20.70
Upside: +1.45%
Rhythm Pharmaceuticals
Feb 19, 2026
Initiates: Outperform
Price Target: $145
Current: $94.94
Upside: +52.73%
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $7.58
Upside: +111.08%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $9.33
Upside: +242.98%
EyePoint
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $18.34
Upside: +112.65%